2003
DOI: 10.1002/pds.913
|View full text |Cite
|
Sign up to set email alerts
|

Identification of patients with Churg–Strauss syndrome (CSS) using automated data

Abstract: Automated claims data can be used to identify patients with CSS. This approach can facilitate better epidemiologic study of the risk factors for the condition.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2005
2005
2021
2021

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 15 publications
0
8
0
Order By: Relevance
“…However, studies evaluating the validity of other diagnoses such as idiopathic thrombocytopenia [12], rhabdomyolysis [13], and ChurgeStrauss syndrome [14] have reported PPVs in the 70e80% range, indicating greater confidence in the use of the administrative data to identify patients with those conditions.…”
Section: Discussionmentioning
confidence: 97%
“…However, studies evaluating the validity of other diagnoses such as idiopathic thrombocytopenia [12], rhabdomyolysis [13], and ChurgeStrauss syndrome [14] have reported PPVs in the 70e80% range, indicating greater confidence in the use of the administrative data to identify patients with those conditions.…”
Section: Discussionmentioning
confidence: 97%
“…[10][11][12] However, a specific diagnosis code for use in identifying patients with EGPA from health records was only established in the United States in October 2015 with the adoption of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM); before ICD-10-CM, studies evaluating the burden of EGPA via retrospective analyses of administrative claims data relied on a series of coding algorithms (eg, International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis and procedures codes, Current Procedural Terminology [CPT] codes, and physician specialties). [13][14][15][16][17][18] Owing to the previous lack of EGPA-specific diagnosis codes and limited number of regulatory approved treatments, data are limited on the clinical and economic burden of EGPA. Comparing clinical outcomes in EGPA with those in patients with asthma, in which the disease burden is well established, 19 is a useful way to measure the burden of EGPA for patients and payers.…”
Section: What This Study Addsmentioning
confidence: 99%
“…Within the asthma drug cohort, we identified cases using the method that we have previously published in detail. 7,8 There were four steps: selection of individuals by claims; abstraction of medical records for patients further screened by physicians using claims patterns; review of medical record abstractions by two physicians (LRH, MKP) for the presence of !2 criteria for CSS based on the American College of Rheumatology (ACR) criteria, except for the situation of combined asthma and sinusitis in which a third criterion was required; 9 and consensus adjudication by two physicians with particular expertise in the diagnosis of CSS (PFW, MEW). The diagnoses of interest used to identify potential cases included vasculitis, eosinophilia, pulmonary eosinophilia, mononeuritis multiplex, and neurologic symptoms.…”
Section: Case Identification and Control Selectionmentioning
confidence: 99%